Ask Warren

JONBUR Research · Initiation

Kanaph Therapeutics · 0082N0 · Biotech & Pharma

Kanaph Therapeutics: Loss-making KOSDAQ biotech trades far below its 52-week high after a 2026 listing

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Kanaph Therapeutics listed on KOSDAQ on 2026-03-16 and closed at ₩10,360 on 2026-10-16, about 85.2% below its 52-week high of ₩70,000. The latest filed numbers show revenue of ₩5.6B, an operating loss of ₩4.3B and a net loss of ₩35.6B.

Written Oct 18, 2026 · Data as of Oct 16, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a picture of an early-stage, loss-making biotech with a small balance sheet burden and a sharply lower share price since listing. The share price fell 9.9% over one month and 16.2% over three months, and the stock sits near its 52-week low of ₩9,170. Liabilities are only 4.4% of equity, and cash was ₩10.1B at the latest filing, which is a strength. Against that, free cash flow was negative ₩7.2B, so the cash balance covers only a limited period at that rate of burn. Foreign ownership fell from 4.8% to 2.7% over 60 days, and institutions were net sellers over the last 20 days (₩3.5B) while retail investors were net buyers (₩3.2B). Recent news mentions data on a dual-antibody ADC presented at World ADC, but the data does not show how this affects revenue or earnings. The data does not include guidance or a trial timeline.

Business overview

Kanaph Therapeutics is a Biotech & Pharma company founded on 2019-02-14 and listed on KOSDAQ on 2026-03-16, with 13,300,580 listed shares. Market capitalization is about ₩137.8B and enterprise value about ₩127.7B. The CEO is listed as 이병철. Only one annual record is available (2025), so there is no multi-year history of revenue growth. Revenue growth is not available. Recent filings include IR events on 2026-09-08 and 2026-10-12, a 5%+ holding report on 2026-09-18, insider shareholding reports and a notice on the grant of stock purchase options on 2026-05-28.

Financial analysis

These figures come from filed financial statements. For the latest period (labeled H1 2026 trailing), revenue was ₩5.6B, operating income was negative ₩4.3B (operating margin -76.8%) and net income was negative ₩35.6B (net margin -639.5%). The net loss is far larger than the operating loss, which indicates large non-operating or financing-related charges, but the data does not break these down. ROE is -76.8% in the trailing figure; the 2025 annual record shows ROE of -287.3%. Liabilities to equity is 4.4%, cash is ₩10.1B, and borrowings are not available. Free cash flow was negative ₩7.2B.

Valuation

With losses, the P/E and EV/EBITDA are not available. Price-to-book is 3.0 and price-to-sales is 24.8. Dividend yield is 0.0%. The company has no valuation history of its own beyond its short listing period, so comparison against its own past multiples is not possible. Listed peers show P/B ratios of 2.5 (Celltrion and Yuhan), 5.6 (SK biopharmaceuticals), 7.2 (Samsung Biologics) and 30.4 (Alteogen), and P/E ratios of 14.3 to 84.4; these are far larger, profitable companies, so the comparison is limited. The valuation model estimate (fair_value_model) is not available because it cannot be worked out for a company with these losses, so there is no model estimate per share to compare with the ₩10,360 price.

Catalysts

  • Recent news on 2026-10-14 reported dual-antibody ADC tumor-suppression data presented at World ADC, which may draw attention to the company's pipeline.
  • IR events were filed on 2026-09-08 and 2026-10-12, showing ongoing investor outreach.
  • A 5%+ holding report was filed on 2026-09-18, which points to changes in major shareholder positions.
  • The notice on Grant of Stock Purchase Options on 2026-05-28 and several insider shareholding reports are visible in filings.
  • The next periodic filing for the September quarter would update losses and cash, though its date is not in the data.

Risks

  • The company is loss-making, with a net margin of -639.5% and an operating margin of -76.8%.
  • Free cash flow of negative ₩7.2B against cash of ₩10.1B limits the runway, and funding plans are not in the data.
  • The share price is near its 52-week low and 85.2% below its high, showing high volatility after listing.
  • Foreign ownership fell from 4.8% to 2.7% and institutions were net sellers over 20 days, indicating weaker demand from those groups.
  • Revenue history is short and growth is not available, and no valuation model estimate can be produced, so visibility on earnings is low.

Closing view

The data shows a recently listed biotech with a clean balance sheet but persistent losses, negative free cash flow and a share price that has fallen sharply from its high. Early scientific news is visible, but the filings and financial data do not show how it converts into revenue or profit. With no valuation model estimate and limited history, the evidence is mixed and leaves substantial uncertainty.

Model estimate of fair value

The valuation model has no estimate for this company yet (not enough data, or no positive value with the base case).

Filings and data used

Report history

  1. Oct 18, 2026InitiationStart of coverage (reader request)Kanaph Therapeutics: Loss-making KOSDAQ biotech trades far below its 52-week high after a 2026 listing

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information